RecruitingPhase 4NCT07600177

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Sponsor

Oregon Health and Science University

Enrollment

40 participants

Start Date

May 5, 2026

Study Type

INTERVENTIONAL

Conditions

Hypertrophic Cardiomyopathy (HCM)

Summary

This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria3

Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially.
Echo-derived LVEF ≥55% on mavacamten at the time of enrollment.
Patient willing to consent for the study and undergo the study procedures.

Exclusion Criteria6

Severe aortic stenosis or sub-aortic obstruction
Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis).
History of LVEF <30%.
Paroxysmal atrial fibrillation (AF) with documented episode within 3 months.
Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation.
Documented history of current obstructive coronary artery disease (> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.